Pharmaceuticals

Curosurf (Poractant Alfa) Market Outlook 2026–2030 Driven By Growth Factors And Projections

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Curosurf (Poractant Alfa) Market Expected To Scale Between 2026 And 2030?

Throughout the historical period, growth was driven by a frequent occurrence of premature births, the established effectiveness in treating respiratory distress syndrome (RDS), the extensive implementation of Neonatal Intensive Care Units (NICUs), clinical recommendations endorsing surfactant therapy, and a decrease in neonatal mortality rates.

Growth during the forecast period is projected to be driven by several factors, including the global rise in premature birth rates, the expansion of Neonatal Intensive Care Unit (NICU) infrastructure, improved accessibility to neonatal care, a growing awareness regarding early intervention for Respiratory Distress Syndrome (RDS), and sustained clinical validation.

Significant trends expected within the forecast period include an increasing application in neonatal intensive care settings, the growing adoption of synthetic surfactants, a heightened focus on the management of preterm births, the standardization of RDS treatment protocols, and the broadening provision of hospital-based neonatal therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp

What Major Factors Are Driving The Curosurf (Poractant Alfa) Market Forward?

The rising occurrence of respiratory conditions is anticipated to fuel the expansion of the curosurf (poractant alfa) market in the future. These disorders encompass prevalent ailments impacting the lungs and respiration, including asthma, COPD, and lung cancer, resulting in breathing difficulties and diminished pulmonary capacity. The growing frequency of respiratory ailments is attributed to increasing air pollution, which worsens conditions like asthma, alongside an aging demographic that contributes to a greater occurrence of age-related illnesses such as COPD. Poractant alfa serves as a treatment for neonatal respiratory distress syndrome, enhancing lung performance and assisting premature infants with breathing when administered through an endotracheal tube. For example, data from the National Library of Medicine, a US-based medical library, published in December 2023, indicates that worldwide chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and above are projected to surge by 23% by 2050, reaching almost 600 million. Consequently, the expanding prevalence of respiratory conditions is propelling the market growth for curosurf (poractant alfa).

What Are The Different Segment Types In The Curosurf (Poractant Alfa) Market Segment Breakdown?

The curosurf (poractant alfa) market covered in this report is segmented –

1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa

2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace

3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders

4) By End User: Hospitals, Clinics, Ambulance Services

What Trends Are Affecting The Direction Of The Curosurf (Poractant Alfa) Market?

Leading companies in the curosurf (poractant alfa) market are concentrating on developing innovative solutions, such as novel inhaled gene therapy, to meet the unmet needs in various respiratory disorders. This cutting-edge approach, novel inhaled gene therapy, involves delivering therapeutic genes directly to the lungs through inhalation, typically using aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based gene therapy developer, obtained Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002, an innovative inhaled gene therapy targeting lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic condition that leads to respiratory failure in infants. SP-B deficiency, which results from mutations in the SFTPB gene, currently has very few treatment options, primarily depending on lung transplantation. AVG-002 leverages AlveoGene’s InGenuity platform to administer a functional SP-B gene directly to the lungs, exhibiting promising results in preclinical studies.

Who Are The Well-Known Companies In The Curosurf (Poractant Alfa) Market?

Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A

Get The Full Curosurf (Poractant Alfa) Market Report:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Which Region Accounts For The Largest Portion Of The Curosurf (Poractant Alfa) Market?

North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Curosurf (Poractant Alfa) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-

Browse Through More Reports Similar to the Global Curosurf (Poractant Alfa) Market 2026, By The Business Research Company

Alfalfa Market Report 2026

https://www.thebusinessresearchcompany.com/report/alfalfa-global-market-report

Compound Camphor Ointment Market Report 2026

https://www.thebusinessresearchcompany.com/report/compound-camphor-ointment-global-market-report

Pharmaceutical Pellets Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-pellets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795